WO1994023028A3 - Modified oligonucleotides having improved anti-influenza activity - Google Patents

Modified oligonucleotides having improved anti-influenza activity Download PDF

Info

Publication number
WO1994023028A3
WO1994023028A3 PCT/US1994/003454 US9403454W WO9423028A3 WO 1994023028 A3 WO1994023028 A3 WO 1994023028A3 US 9403454 W US9403454 W US 9403454W WO 9423028 A3 WO9423028 A3 WO 9423028A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified oligonucleotides
improved anti
influenza activity
influenza
greater efficacy
Prior art date
Application number
PCT/US1994/003454
Other languages
French (fr)
Other versions
WO1994023028A2 (en
Inventor
Sudhir Agrawal
Jin-Yan Tang
Abeysinghe Padmarpiya
Original Assignee
Hybridon Inc
Sudhir Agrawal
Tang Jin Yian
Padmarpriya Abeysinghe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc, Sudhir Agrawal, Tang Jin Yian, Padmarpriya Abeysinghe filed Critical Hybridon Inc
Priority to EP94912901A priority Critical patent/EP0693123A1/en
Priority to JP6522317A priority patent/JPH08510900A/en
Priority to AU65270/94A priority patent/AU6527094A/en
Publication of WO1994023028A2 publication Critical patent/WO1994023028A2/en
Publication of WO1994023028A3 publication Critical patent/WO1994023028A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

The invention provides anti-influenza modified oligonucleotides that have greater efficacy in inhibiting influenza replication or propagation than previously described oligonucleotides. The greater efficacy arises from structural features such as chimeric or hybrid backbones, nuclease resistance-conferring terminal capping structures and/or self-complementary regions.
PCT/US1994/003454 1993-03-31 1994-03-30 Modified oligonucleotides having improved anti-influenza activity WO1994023028A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94912901A EP0693123A1 (en) 1993-03-31 1994-03-30 Modified oligonucleotides having improved anti-influenza activity
JP6522317A JPH08510900A (en) 1993-03-31 1994-03-30 Modified oligonucleotides with improved anti-influenza activity
AU65270/94A AU6527094A (en) 1993-03-31 1994-03-30 Modified oligonucleotides having improved anti-influenza activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4075293A 1993-03-31 1993-03-31
US08/040,752 1993-03-31

Publications (2)

Publication Number Publication Date
WO1994023028A2 WO1994023028A2 (en) 1994-10-13
WO1994023028A3 true WO1994023028A3 (en) 1995-02-16

Family

ID=21912738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003454 WO1994023028A2 (en) 1993-03-31 1994-03-30 Modified oligonucleotides having improved anti-influenza activity

Country Status (7)

Country Link
EP (1) EP0693123A1 (en)
JP (1) JPH08510900A (en)
CN (1) CN1124980A (en)
AU (1) AU6527094A (en)
CA (1) CA2159350A1 (en)
NZ (1) NZ263985A (en)
WO (1) WO1994023028A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT733059E (en) * 1993-12-09 2001-03-30 Univ Jefferson COMPOUNDS AND METHODS FOR LOCAL MUTACOES IN EUCARIOTIC CELLS
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
AU5325696A (en) * 1995-04-03 1996-10-23 Hybridon, Inc. Method of modulating gene expression without depleting compl ement
US6372427B1 (en) * 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
WO1997038097A1 (en) * 1995-04-12 1997-10-16 Hybridon, Inc. Cooperative oligonucleotides
GB9511720D0 (en) * 1995-06-09 1995-08-02 Isis Innovation Oligonucleotide phosphorylation method and products
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP1007656B1 (en) * 1997-03-12 2006-09-13 Idera Pharmaceuticals, Inc. Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use
GB9710044D0 (en) * 1997-05-16 1997-07-09 Innes John Centre Innov Ltd A plant disease resistance signalling gene: materials and methods relating thereto
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
EP1951737A4 (en) 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc Rnai inhibition of influenza virus replication
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2550002B1 (en) 2010-03-24 2019-05-08 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
KR20160110370A (en) 2013-12-04 2016-09-21 알엑스아이 파마슈티칼스 코포레이션 Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN107073294A (en) 2014-09-05 2017-08-18 阿克赛医药公司 Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder
CA2991598A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386563A1 (en) * 1989-03-09 1990-09-12 Bayer Ag Antisense-oligonucleotides for inhibiting the transactivator target sequence (TAR) and the synthesis of the transactivator protein (Tat) of HIV-I, and their use
WO1991012323A1 (en) * 1990-02-15 1991-08-22 Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
WO1991016902A1 (en) * 1990-04-30 1991-11-14 Hybridon, Inc. Inhibition of influenza virus replication by oligonucleotides
WO1992003454A1 (en) * 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386563A1 (en) * 1989-03-09 1990-09-12 Bayer Ag Antisense-oligonucleotides for inhibiting the transactivator target sequence (TAR) and the synthesis of the transactivator protein (Tat) of HIV-I, and their use
WO1991012323A1 (en) * 1990-02-15 1991-08-22 Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
WO1991016902A1 (en) * 1990-04-30 1991-11-14 Hybridon, Inc. Inhibition of influenza virus replication by oligonucleotides
WO1992003454A1 (en) * 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATABEKOV, K. ET AL.: "Site-specific enzymatic cleavage of TMV RNA directed by deoxyribo- and chimeric (deoxyribo-ribo)oligonucleotides", FEBS LETTERS, vol. 232, no. 1, May 1988 (1988-05-01), AMSTERDAM NL, pages 96 - 98 *
ZHOU, L. ET AL.: "Synthesis of phosphorothioate-methylphosphonate oligonucleotide co-polymers", NUCLEIC ACIDS RESEARCH, vol. 22, no. 3, 11 February 1994 (1994-02-11), ARLINGTON, VIRGINIA US, pages 453 - 456 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Also Published As

Publication number Publication date
CA2159350A1 (en) 1994-10-13
EP0693123A1 (en) 1996-01-24
JPH08510900A (en) 1996-11-19
CN1124980A (en) 1996-06-19
WO1994023028A2 (en) 1994-10-13
AU6527094A (en) 1994-10-24
NZ263985A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
WO1994023028A3 (en) Modified oligonucleotides having improved anti-influenza activity
ZA966584B (en) Blooming type, hard surface cleaning and/or disinfecting compositions.
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO1998006742A3 (en) Peptides for treatment of inflammation and shock
AU2001236791A1 (en) Systems for the prevention or treatment of carpal tunnel syndrome
EP1015011A4 (en) Peptide nucleic acids having antibacterial activity
WO2001060157A3 (en) Antibacterial agents and compositions
WO2002102388A3 (en) Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism
WO1995006764A3 (en) Oligonucleotides with rna cleavage activity
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EP0643142A3 (en) Prevention of particle embrittlement in grain-refined, high strength steels.
WO2003015797A8 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
EP1016403A3 (en) Skin cleansing composition
EP1240902A4 (en) Carbonyl stress-ameliorating agents
WO2001095946A3 (en) Combination product for carrying out a cytotoxic treatment in a mammal
WO2002020091A3 (en) Antithrombotic compositions
ZA200200617B (en) Surfactant emulsions and structured surfactant systems.
WO1998018818A3 (en) Hepatitis b inhibitors
CA2216004A1 (en) Improved rinse aid compositions containing phosphate esters
WO2001049316A3 (en) Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
WO2000032166A3 (en) Microparticles containing water insoluble active agents
WO2002048372A3 (en) Target enzymes
AU5733696A (en) Compositions comprising bismuth and one or more antimicrobia ls, for the treatment and prevention of gastrointestinal dis orders
魏志勇 et al. THE CORRELATED CROSS SECTION OF THE MANY-BODY SCATTERING

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192300.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2159350

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 263985

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994912901

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994912901

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1994912901

Country of ref document: EP